Investigational Drug Details
| Drug ID: | D380 |
| Drug Name: | TVB-2640 |
| Synonyms: | FASN Inhibitor |
| Type: | Chemical drug |
| DrugBank ID: | -- |
| DrugBank Description: | -- |
| PubChem ID: | 66548316 |
| CasNo: | 1987917-56-5 |
| Repositioning for NAFLD: | No |
| SMILES: | O=C(N1CCC(CC1)c1ccc(cc1)C#N)c1c(cc(C2CCC2)c(c1)c1nc([nH]n1)C)C |
| Structure: |
|
| InChiKey: | BBGOSBDSLYHMRA-UHFFFAOYSA-N |
| Molecular Weight: | 439.563 |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | FASN inhibitor |
| Therapeutic Category: | Enhance lipid metabolism; Anticancer agent |
| Clinical Trial Progress: | Phase 2 on-going (NCT04906421); Phase 2 completed (NCT03938246: TVB-2640 significantly reduced liver fat and improved biochemical, inflammatory, and fibrotic biomarkers after 12 weeks, in a dose-dependent manner in patients with nonalcoholic steatohepatitis. ) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0385 | NCT04906421 | Phase 2 | Recruiting | No Results Available | 20/05/2021 | 21 February 2022 | Details |
| L0468 | NCT03938246 | Phase 2 | Not recruiting | No Results Available | 24/04/2019 | 8 November 2021 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S02 | Enhance lipid metabolism | triglyceride-lowering; lipid tolerance; lipid metabolism | 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitor; Decreases intestinal cholesterol absorption; FXR agonist; ACC inhibitor; FAS inhibitor; DGAT2 inhibitor; SCD-1 inhibitor | Atorvastatin; Ezetimibe; Obeticholic Acid; GS-9674; GS-0976; TVB-2640; IONIS-DGAT2rx; Aramchol; | Details |
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A02610 | 34310978 | Gastroenterology | TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. | Details |
| A09740 | 31630414 | Hepatology | Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities. | Details |
| A43023 | 32781957 | Mini Rev Med Chem | Recent Advances in the Development of Fatty Acid Synthase Inhibitors as Anticancer Agents. | Details |